昊帆生物
(301393)
| 流通市值：17.95亿 | | | 总市值：48.03亿 |
| 流通股本：4035.90万 | | | 总股本：1.08亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 451,874,668.1 | 328,158,737.06 | 225,057,269.42 | 91,229,728.71 |
| 营业收入 | 451,874,668.1 | 328,158,737.06 | 225,057,269.42 | 91,229,728.71 |
| 二、营业总成本 | 320,336,611.16 | 228,599,500.59 | 151,713,429.68 | 61,494,588.69 |
| 营业成本 | 269,852,206.07 | 191,553,471 | 134,681,268.22 | 56,531,270.9 |
| 税金及附加 | 4,178,065.22 | 2,553,778.66 | 1,857,431.67 | 600,805.24 |
| 销售费用 | 13,596,937.8 | 9,686,865.68 | 7,533,851.66 | 2,182,431.61 |
| 管理费用 | 29,529,803.99 | 23,460,639.15 | 15,265,464.08 | 5,731,275.77 |
| 研发费用 | 35,991,848.34 | 26,225,248.09 | 16,908,969.96 | 10,389,895.99 |
| 财务费用 | -32,812,250.26 | -24,880,501.99 | -24,533,555.91 | -13,941,090.82 |
| 其中:利息费用 | 91,293.5 | 34,786.56 | 22,939.98 | 16,356.33 |
| 其中:利息收入 | 29,727,232.8 | 28,050,784.16 | 23,623,486.51 | 12,439,672.85 |
| 加:公允价值变动收益 | 5,636,108.35 | 8,537,868.52 | 1,848,635.62 | 277,995.89 |
| 加:投资收益 | 10,950,889.64 | 1,172,551.34 | 168,632.16 | - |
| 资产处置收益 | -32,052.89 | -58,976.15 | - | - |
| 资产减值损失(新) | -2,661,553.64 | -1,369,210.16 | -2,777,892.49 | 634,404.65 |
| 信用减值损失(新) | -2,509,435.62 | -3,248,675.25 | -2,965,500.21 | -1,253,202.7 |
| 其他收益 | 12,969,342.67 | 6,400,906.92 | 5,842,163.57 | 4,774,574.41 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 155,891,355.45 | 110,993,701.69 | 75,459,878.39 | 34,168,912.27 |
| 加:营业外收入 | 120,434.03 | 118,889.22 | 115,874.22 | 101,495.01 |
| 减:营业外支出 | 1,375,650.43 | 565,246.74 | 104,005.11 | 41,247.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 154,636,139.05 | 110,547,344.17 | 75,471,747.5 | 34,229,159.78 |
| 减:所得税费用 | 20,583,221.99 | 14,212,148.52 | 9,662,664.28 | 4,400,320.04 |
| 六、净利润 | 134,052,917.06 | 96,335,195.65 | 65,809,083.22 | 29,828,839.74 |
| 持续经营净利润 | 134,052,917.06 | 96,335,195.65 | 65,809,083.22 | 29,828,839.74 |
| 归属于母公司股东的净利润 | 134,052,917.06 | 96,335,195.65 | 65,809,083.22 | 29,828,839.74 |
| (一)基本每股收益 | 1.25 | 0.9 | 0.61 | 0.28 |
| (二)稀释每股收益 | 1.24 | 0.89 | 0.61 | 0.28 |
| 九、综合收益总额 | 134,052,917.06 | 96,335,195.65 | 65,809,083.22 | 29,828,839.74 |
| 归属于母公司股东的综合收益总额 | 134,052,917.06 | 96,335,195.65 | 65,809,083.22 | 29,828,839.74 |
| 公告日期 | 2025-04-11 | 2024-10-30 | 2024-08-28 | 2024-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |